BiVACOR Names Veteran Medical Device Executive Jim Dillon as Chief Executive Officer

Preview

来源: Business Wire

'Jim\u2019s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR'

Preview

来源: Business Wire

HUNTINGTON BEACH, Calif. & HOUSTON & GOLD COAST, Australia--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors.

Mr. Dillon is an experienced medical device executive whose career focus in heart failure has included developing cardiovascular therapies to enable native heart recovery, reducing the size of a patient’s myocardial infarction, repairing adult and congenital cardiac defects, and volume management for acutely decompensated congestive heart failure patients.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” stated Raymond W. Cohen, Chairman of the Board of BiVACOR. “We are thrilled to have him join as CEO.”

Over his multi-decade career, Mr. Dillon has held a series of corporate strategic and sales leadership positions as a key contributor to multiple successful medical device companies. Prior to his recent role as CEO of clinical-stage private company BioVentrix, he held senior executive sales and marketing positions with Abiomed, TherOx, and InfraReDx.

“It’s a privilege to lead the BiVACOR team at a pivotal time in the company’s history,” said Mr. Dillon. “A Total Artificial Heart (TAH) is unique in its complexity and importance as an advanced treatment option for end-stage biventricular heart failure patients. The BiVACOR TAH device has the potential to truly revolutionize the field.”

In late November, BiVACOR announced that the U.S. Food and Drug Administration approved an investigational device exemption allowing the company to conduct a first-in-human clinical feasibility study of the BiVACOR TAH. The study will evaluate the safety and feasibility of the TAH as a bridge to heart transplant in the treatment of subjects with biventricular heart failure. Initially, three patients will be enrolled at The Texas Heart Institute in Houston. The study is anticipated to commence in the first half of 2024.

About BiVACOR®

BiVACOR® is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart, designed to be the first long-term therapy for patients with severe biventricular heart failure. The BTAH is designed to replace the native heart and address the global unmet need of patients with end-stage heart failure by providing a next-generation life-extending solution.

BiVACOR was founded in 2008 by a team of internationally renowned biomedical engineers and cardiac surgeons, including Founder and Chief Technical Officer Daniel Timms, Ph.D., and Chief Medical Officer William Cohn, MD, and is an international organization with operations in Huntington Beach, CA, Houston, TX, and Gold Coast, Australia.

Today, BiVACOR has a robust collaborative network that extends nationally and internationally and boasts a team of world-class engineers, medical specialists, and business executives fervently working to advance this ground-breaking technology. Core to BiVACOR and its culture is collaboration, working hard, and recognizing those around them.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。